Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioClinica, a global provider of clinical trial management solutions, has reported total revenues of $19.67m for the first quarter ended 31 March 2011, compared to $18.1m for the same period in 2010.
Subscribe to our email newsletter
For the first quarter of 2011, the company has reported a net income of $351,000, or $0.02 per diluted share, compared to $711,000 or $0.05 per diluted share, for the same period last year.
BioClinica‘s income from operations was $567,000 for the first quarter ended 31 March 2011, as compared to $1.17m, for the same period prior year.
BioClinica president and CEO Mark Weinstein said this quarter represents their 5th consecutive quarter of year-over-year growth in service revenue, reflecting the traction they have made in the industry as clients look to them to provide a broad array of services.
"We are reiterating our expectations for full-year 2011 service revenue to be in the range of $66 to $70m, our full-year GAAP EPS, including a restructuring charge of $0.06 per share, to be in the range of $0.16 to $0.21 per diluted share, and our full-year non-GAAP EPS to be in the range of $0.30 to $0.35 per diluted share," Weinstein said.